Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. MU
3. FDX
4. SPY
5. META
6. ABBV
7. ACN
8. NVDA
9. BLZE
10. IBM

Go back to Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) Delayed: 56.50 --0 (-0%)
Previous Close $56.50    52 Week High $108.96 
Open $56.50    52 Week Low $62.12 
Day High $56.50    P/E N/A 
Day Low $56.50    EPS $-1.27 
Volume 99       

Medivation, Inc. (NASDAQ: MDVN) Delayed: 81.44 --0 (-0%)
Previous Close $81.44    52 Week High $81.48 
Open $3852.47    52 Week Low $26.41 
Day High $81.44    P/E N/A 
Day Low $81.44    EPS $-1.03 
Volume 13,593       

BANCO SANTANDER S.A. (NYSE: SAN) Delayed: 13.60 --0 (-0%)
Previous Close $13.60    52 Week High $5.58 
Open $13.60    52 Week Low $3.60 
Day High $13.60    P/E N/A 
Day Low $13.60    EPS $0.00 
Volume 88,258       

SANOFI (NASDAQ: SNY) Delayed: 41.60 --0 (-0%)
Previous Close $41.60    52 Week High $44.76 
Open $41.60    52 Week Low $36.81 
Day High $41.60    P/E N/A 
Day Low $41.60    EPS $0.00 
Volume 1,676